NASDAQ:OPGN
OpGen, Inc. Stock News
$0.535
+0.0201 (+3.90%)
At Close: Apr 29, 2024
Curetis N.V. : in liquidatie informs on publication of audited FY2019 financial results and annual report | MarketScreener
06:35am, Wednesday, 01'st Jul 2020Top Stocks To Short During Current Market Sell Off
12:00am, Wednesday, 24'th Jun 2020
If you’re looking for some hedges for your portfolio or are looking to shift against the market, our deep learning algorithms and AI technology have several Top Shorts for you today.
Price Over Earnings Overview: OpGen
02:28pm, Tuesday, 09'th Jun 2020
Looking into the current session, OpGen Inc. (NASDAQ: OPGN) shares are trading at $2.13, after a 7.03% spike. Moreover, over the past month, the stock went up by 4.93%, but in the past year, fell by 7
OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today preliminary da
OpGen Expands Partnership with New York State Department of Health and IDC to Detect Antimicrobial-Resistant Infections
10:00am, Wednesday, 03'rd Jun 2020
OpGen, Inc. (OPGN) announced today that its strategic collaboration with the New York State Department of Health (“DOH”) to develop a state-of-the-art solution to detect, track, and manage antimic
Edited Transcript of OPGN earnings conference call or presentation 7-May-20 8:30pm GMT
05:01pm, Monday, 11'th May 2020
Q1 2020 OpGen Inc Earnings Call
OpGen CEO and Chairman of the Board Issue Letters to Stockholders
11:30am, Monday, 11'th May 2020
OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, to issued two letters to stockhol
OpGen, Inc. (OPGN) CEO Oliver Schacht on Q1 2020 Results - Earnings Call Transcript
04:24am, Sunday, 10'th May 2020
Start Time: 16:30 End Time: 17:13 OpGen, Inc. (NASDAQ:OPGN) Q1 2020 Earnings Conference Call May 07, 2020, 16:30 PM ET Company Participants Oliver Schacht - CEO
OpGen Reports First Quarter 2020 Financial Results and Provides Business Update
08:05pm, Thursday, 07'th May 2020
Total Revenue for Q1 2020 was approximately $617,000 (excluding Curetis Revenue)Curetis and Ares revenue was approximately $900,000 for the first quarter generating a pro forma.
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
12:00am, Thursday, 07'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 6.)
Adverum Biotechnologies Inc...
Teladoc's (TDOC) Q1 Earnings Miss Estimates, Revenues Beat
03:47pm, Thursday, 30'th Apr 2020
Teladoc's (TDOC) first-quarter earnings gain from higher revenues, partly offset by a rise in expenses.
Curetis N.V. in liquidatie informs on delay of publication of audited FY2019 financial results and annual report | MarketScreener
06:00am, Thursday, 30'th Apr 2020OpGen to Provide Business Update and Financial Results for the First Quarter 2020
12:30pm, Monday, 27'th Apr 2020
GAITHERSBURG, Md., April 27, 2020 -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its first.
BYND, OPK among premarket gainers
01:16pm, Tuesday, 21'st Apr 2020
Energous (NASDAQ:WATT) +143% on FCC certification.Vaxart (NASDAQ:VXRT) +32% on encouraging COVID-19 vaccine data.My Size (NASDAQ:MYSZ) +27%.Applied DNA Sciences (NASDAQ:APDN) +21% on deal for COVID
OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today the start of a
